News

Public · Published

TME Pharma N.V. (ALTME) H1 Loss €0.51M; Cash €1.02M

TME Pharma reported a half-year net loss of €0.51M, narrower than the €2.1M loss a year earlier, with no revenue and cash of €1.02M at June 30, 2026. Equity remained negative at €2.61M.

Published:

Updated:

What happened

TME Pharma reported a half-year net loss of €0.51M, narrower than the €2.1M loss a year earlier, with no revenue and cash of €1.02M at June 30, 2026. Equity remained negative at €2.61M.

Confirmed

Global impact / market context

The smaller loss shows cost cuts slowing the company's cash use, but with no revenue, €1.02M of cash is a thin cushion. Negative equity of €2.61M raises near-term financing risk and may push the company toward fresh fundraising or a funding deal.

Analyst inference

This is an early-stage biotech balancing deep spending cuts against a weak balance sheet. Reduced research spending saves cash but can delay its drug program. Investors are likely to focus on whether new financing or a partnership arrives before cash runs low.

Analyst inference

What to watch

  1. Watch whether TME Pharma secures fresh financing or a funding deal before its €1.02M cash balance runs low, since no revenue was reported. Confirmed
  2. A definitive deal to fund the NOX-A12/GLORIA program is cited as a potential catalyst that would extend the company's cash runway. Proposed
  3. Track whether negative equity of €2.61M triggers lender covenants or forces capital measures such as a share issue, which could dilute existing investors. Analyst inference

Evidence